Generation-Dependent Retention Rates and Reasons for Discontinuation of Molecular Targeted Therapies in Patients with Rheumatoid Arthritis: From FIRST Registry
ConclusionsThe study highlights the need to consider different age groups separately in elderly RA care. Among patients aged 75 years and older, abatacept and anti-IL-6R antibodies showed the highest continuation rates, suggesting their potential suitability and efficacy for this specific age cohort.
Source: Rheumatology and Therapy - Category: Rheumatology Source Type: research
More News: Abatacept | Arthritis | Japan Health | Orencia | Rheumatoid Arthritis | Rheumatology | Study